SCHEMBL30446809

SCHEMBL30446809

Nc1cccc(C(CCC2CC2)c2ccccc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.40
CPN1 P15169 1/20 0.40
CPB2 Q96IY4 1/20 0.40
CYP2D6 P10635 1/20 0.39
KLKB1 P03952 1/20 0.38
HTR2A P28223 1/20 0.38
CYP19A1 P11511 1/20 0.37
MAOA P21397 3/20 0.37
MAOB P27338 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
GFER P55789 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KCNA3 P22001 1/20 0.36
PDE4A P27815 1/20 0.36
SOS1 Q07889 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17064662 1.00 HRH1 (0.40) HRH1CPN1CPB2CYP2D6KLKB1
SCHEMBL17064585 0.90 MAPKAPK2 (0.41) CPN1CPB2KLKB1CYP19A1MAPT
SCHEMBL30466449 0.84 MEN1 (0.41) MEN1LMNAPDE4A
SCHEMBL17064512 0.84 MEN1 (0.41) MEN1LMNAPDE4A
SCHEMBL17064729 0.83 ALDH1A1 (0.44) HRH1CYP2D6HTR2AKDM4EMEN1
SCHEMBL17073423 0.82 CPN1 (0.41) CPN1CPB2
SCHEMBL31067489 0.82 CPN1 (0.41) CPN1CPB2
SCHEMBL25667743 0.81 CPN1 (0.36) CPN1CPB2CYP2D6MAOAMAOB
SCHEMBL17064816 0.79 HRH1 (0.40) HRH1CYP2D6KLKB1HTR2ACYP19A1
SCHEMBL486888 0.78 HRH1 (0.69) HRH1CPN1CPB2CYP2D6HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-28 US disclosed
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-14 US disclosed
CN-113307772-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2024-06-28 CN disclosed
US-11685721-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 HRH1 829/4885CPN1 553/4885CPB2 79/4885
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 HRH1 829/4885CPN1 553/4885CPB2 79/4885
US-11685721-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 HRH1 829/4885CPN1 553/4885CPB2 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.